Understanding the Market | MORIMATSU INTL rises over 9%, new orders signed in the first half exceed expectations, and the company will benefit from the release of overseas pharmaceutical momentum
MORIMATSU INTL's stock price rose by more than 9%, with an increase of 9.38% as of the time of publication, trading at HKD 10.84, with a transaction volume of HKD 177 million. The company signed new orders worth RMB 5.996 billion in the first half of the year, a year-on-year increase of 89.5%, of which pharmaceutical orders amounted to RMB 4.372 billion, a year-on-year increase of 642%. The backlog of orders is RMB 10.566 billion, a year-on-year increase of 20.4%. Huatai Securities expects the company to resume double-digit net profit growth in the future
According to Zhitong Finance APP, MORIMATSU INTL (02155) rose over 9%, as of the time of writing, up 9.38% to HKD 10.84, with a transaction volume of HKD 177 million.
In terms of news, in the first half of this year, MORIMATSU INTL signed new orders worth 5.996 billion yuan, a year-on-year increase of 89.5%. Among them, new orders in the pharmaceutical sector amounted to 4.372 billion yuan, a year-on-year increase of 642%. As of the first half of this year, the company's backlog of orders was 10.566 billion yuan, a year-on-year increase of 20.4%, setting a historical high. Huatai Securities believes that the main reason is the strong recovery of overseas pharmaceutical CAPEX demand, and the company has effectively converted orders by seizing opportunities. The firm expects the company's net profit attributable to the parent company to see slight year-on-year growth in 2025. However, with the reduction of impairment losses and the potential significant growth of new orders in 2025, the company is expected to resume double-digit year-on-year growth in net profit attributable to the parent company starting in 2026.
Additionally, on September 25 local time, U.S. President Trump announced that starting October 1, the U.S. will implement a new round of high tariffs on various imported products. This time, Trump stated that unless companies have already begun construction of manufacturing plants in the U.S., a new 100% tariff on all branded or patented drugs will apply to all imported products. Public information shows that MORIMATSU INTL, as an internationally leading one-stop comprehensive solution provider, has rich experience in high-end equipment/process modules/modular factory projects, with significant advantages in quality, delivery time, and pricing
